Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2011-03-22
2011-03-22
Harris, Alana M (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C424S133100, C424S134100, C424S135100, C424S136100, C424S138100, C424S144100, C424S152100, C424S154100, C424S155100, C424S156100, C424S174100, C424S178100, C424S181100, C424S183100, C530S350000, C530S386000, C530S387100
Reexamination Certificate
active
07910103
ABSTRACT:
B-cell malignancies, such as the B-cell subtype of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, are significant contributors to cancer mortality. The response of B-cell malignancies to various forms of treatment is mixed. Traditional methods of treating B-cell malignancies, including chemotherapy and radiotherapy, have limited utility due to toxic side effects. Immunotherapy with anti-CD20 antibodies have also provided limited success. The use of antibodies that bind with the CD22 or CD19 antigen, however, provides an effective means to treat B-cell malignancies such as indolent and aggressive forms of B-cell lymphomas, and acute and chronic forms of lymphatic leukemias. Moreover, immunotherapy with anti-CD22 and/or anti-CD19 antibodies requires comparatively low doses of antibody protein, and can be used effectively in multimodal therapies.
REFERENCES:
patent: 5106955 (1992-04-01), Endo et al.
patent: 5484892 (1996-01-01), Tedder et al.
patent: 5686072 (1997-11-01), Uhr et al.
patent: 5698178 (1997-12-01), Goldenberg
patent: 5789554 (1998-08-01), Leung et al.
patent: 6183744 (2001-02-01), Goldenberg
patent: 6306393 (2001-10-01), Goldenberg
patent: 510 949 (1992-04-01), None
patent: WO 95/09917 (1995-04-01), None
patent: WO 96/04925 (1996-02-01), None
patent: WO 98/42378 (1998-01-01), None
patent: WO 99/02567 (1999-01-01), None
Li et al. The Epitope Specificity and Tissue Reactivity of Four Murine Monoclonal Anti-CD22 Antibodies, Cellular Immunology 118: 85-99, 1989.
Rudikoff et al. Single amino acid substitution altering antigen-binding specificity. Proc. Natl. Acad. Sci. USA 79: 1979-1983, Mar. 1982.
Webster's II New Riverside University Dictionary, p. 307, Houghton Mifflin Company, Boston, MA, 1984.
S. Kiesel et al. “Removal of Cells from a malignant B-cell line from bone marrow with immunomagnetic beads and with complement . . . ” Leukemia Research vol. II, No. 12, 1987, pp. 1119-1125.
D. Maloney et al. “Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal Antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma” Blood, vol. 84, No. 8, 1994, pp. 2457-2466.
D. Flavell et al., “Systematic Therapy with 3BIT, a triple combination cocktail of anti-CD19, -CD22, and -CD38-Saporin Immunotoxin, is curative of human B-Cell . . . ” Cancer Research, vol. 57, No. 21, Nov. 1997, pp. 4824-4829.
Green et al., “Antigen-specific human monoclonal antibodies from mice engineered with hum.Ig heavy and light Chain YACS”, Nature Genetic, vol. 7, pp. 13-21, vol. 1, May 1994.
R. French et al., “Response of B-cell lymphomato a combination of bispecific antibodies and saporin” Leukemia Research, vol. 20, No. 7, Jul. 1996, pp. 607-617.
C. Renner et al. “Monoclonal antibodies in the treatment of non-Hodgkin's Lymphoma: recent results and Future Prospects” Leukemia, vol. 11, No. suppl.2, Apr. 1997, 555-59.
Kaminski et al., “Radioimmunotheraphy of B-Cell lymphoma with [131] Anti-B1 [Anti-CD20] Antibody”, New England J. of Medicine 329(7):459-465, Aug. 12, 1993.
Juweid et al., “Treatment of non-hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22”, Cancer Research (Suppl.) vol. 55, pp. 5899s-5907s, Dec. 1, 1995.
Kreitman, R. et. al. Pseudomonas Exotoxin-based Immunotoxins Containing the Antibody LL2 or LL2-Fab' Induce Regression of Subcutaneous Human B-Cell Lymphomas in Mice, Cancer Research 53:819-825, Feb. 15, 1993.
Oliver W. Press; “Prospects for the Management of Non-Hodgkin's Lymphomas with Monoclonal Antibodies and Immunoconjugates”; The Cancer Journal from Scientific American, vol. 4, Supplement 2, pp. S19-S26, 1998.
M. Ghetie et al., “Evaluation of Ricin A Chain-containing Immunotoxins Directed against CD19 and CD22 Antigens on Normal and Malignant Human B-Cells as Potential Reagents for in Vivo Therapy,” Cancer Research, 1988, 48, 2610-2617.
J. Leonard et al., “Epratuzumab, a New Anti-CD22, Humanized, Monoclonal Antibody for the Therapy of Non-Hodgkin's Lymphoma (NHL): Phase I/II Trial Results,” Blood, vol. 94, No. 10 suppl. 1 part 1, 1999, Abstract #404.
W. M. J. Vuist et al., “Potentiation by Interleukin 2 of Burkitt's Lymphoma Therapy with Anti-Pan B (Anti-CD19) Monoclonal Antibodies in a Mouse Xenotransplantation Model,” Cancer Research, Jul. 15, 1989, 49, 3783-3788.
Harris Alana M
Immunomedics Inc.
Rossi Kimms & McDowell LLP
LandOfFree
Immunotherapy of B-cell malignancies using anti-CD22 antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunotherapy of B-cell malignancies using anti-CD22 antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunotherapy of B-cell malignancies using anti-CD22 antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2745527